DRI Healthcare Trust to Host Second Quarter Earnings Call and Webcast on August 15, 2023
TORONTO, July 25, 2023 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") announced today it will hold a conference call to discuss its second quarter 2023 financial results on Tuesday, August 15, 2023, at 8:00 a.m. ET. The Trust will report its financial results on Monday, August 14, 2023, after market close.
All interested parties may join the conference call by dialing 416-764-8659 or 1-888-664-6392 approximately 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins. A question-and-answer session will follow management's prepared remarks, at which time the operator will provide instructions for qualified equity analysts to submit questions.
A live webcast of the conference call, including a slide presentation, will be available at https://bit.ly/3Dj2RNK. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on the Trust's website following the call date.
DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI Capital"), the pioneer in global pharmaceutical royalty monetization with a more than 30-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since our founding in 1989, DRI Capital has deployed more than US$2.5 billion, acquiring more than 70 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". To learn more, visit drihealthcare.com or follow us on LinkedIn. References in this news release to "DRI Healthcare" refer to the Trust and its subsidiaries, on a consolidated basis.
SOURCE DRI Healthcare Trust
David Levine, Director, Investor Relations, Tel: (416) 324-5738, [email protected]
Share this article